Pharmacological target therapy of neuropathic pain and patient-reported outcomes in patients with chronic low back pain in Korea

Results from the NLBP Outcomes Research

Jae Taek Hong, Jin Hwan Kim, Keun Su Kim, Chong Suh Lee, Hyun Chul Shin, Woo Kyung Kim, Joo Han Kim, Jung Kil Lee, In Soo Kim, Yoon Ha, Soo Bin Im, Sang Woo Kim, In Ho Han, Jun Jae Shin, Byeong Cheol Rim, Kyung Soo Suk, Jin Hyok Kim, Ye Soo Park, Bong Soon Chang, Deuk Soo Jun & 10 others Young Hoon Kim, Jung Hee Lee, Woo Kie Min, Jung Sub Lee, Si Young Park, In Soo Oh, Jae-Young Hong, Bo Jeong Seo, Young Joo Kim, Juneyoung Lee

Research output: Contribution to journalArticle

Abstract

A number of studies have demonstrated an association of neuropathic pain and chronic low back pain (CLBP), but the outcome difference in each medical management is poorly understood. This study is aimed to investigate treatment patterns of neuropathic pain in CLBP patients and to explore patient-reported outcomes (PROs) including quality of life (QoL) and functional disability by treatment patterns.Data were extracted from the neuropathic low back pain (NLBP) outcomes research. It was a multicenter and cross-sectional study in which 1200 patients were enrolled at 27 general hospitals, from 2014 to 2015. Of total, 478 patients classified as neuropathic pain were used for this subgroup analysis. The patients were divided into 2 groups according to treatment patterns (with vs. without the targeted therapy [TT] of neuropathic pain). Demographic and clinical features were collected by chart reviews and PROs were measured by patient's survey. QoL was assessed by EuroQoL 5-dimension (EQ-5D) questionnaire. Functional disability was measured by the Quebec Back Pain Disability Scale (QBPDS). Multiple linear regression analyses were conducted to compare the PROs between TT group and non-targeted therapy (nTT) group.Among the NLBP patients (mean age 63years, female 62%), EQ-5D index, EuroQoL-Visual Analog Scale (EQ-VAS), and QBPDS Scores (mean ± standard deviation) were 0.40 ± 0.28, 54.98 ± 19.98, and 46.03 ± 21.24, respectively. Only 142 (29.7%) patients had pharmacological TT of neuropathic pain. Univariate analyses revealed no significant mean differences between TT group and nTT group in the EQ-5D index (0.41 ± 0.27 and 0.39 ± 0.28), EQ-VAS (56.43 ± 18.17 and 54.37 ± 20.69), and QBPDS (45.31 ± 21.32 and 46.31 ± 21.24). After adjustment with covariates, TT group had higher scores of EQ-5D index (β = 0.07; P < 0.01) and EQ-VAS (β = 4.59; P < 0.05) than the nTT group. The TT group's QBPDS score was lower than the nTT group, although its statistical significance still has not been reached (β = -4.13; P = 0.07).We found that considerable proportion of the NLBP patients remains untreated or undertreated. Although TT group had significantly better QoL than nTT group, only 29.7% of NLBP patients had pharmacological TT. Therefore, clinicians should consider using TT for better QoL of neuropathic pain patients.

Original languageEnglish
Pages (from-to)e11919
JournalMedicine
Volume97
Issue number35
DOIs
Publication statusPublished - 2018 Aug 1

Fingerprint

Neuralgia
Korea
Group Psychotherapy
Low Back Pain
Outcome Assessment (Health Care)
Pharmacology
Quebec
Back Pain
Visual Analog Scale
Quality of Life
Therapeutics
Patient Reported Outcome Measures
Social Adjustment
General Hospitals
Linear Models
Cross-Sectional Studies
Regression Analysis
Demography

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Pharmacological target therapy of neuropathic pain and patient-reported outcomes in patients with chronic low back pain in Korea : Results from the NLBP Outcomes Research. / Hong, Jae Taek; Kim, Jin Hwan; Kim, Keun Su; Lee, Chong Suh; Shin, Hyun Chul; Kim, Woo Kyung; Kim, Joo Han; Lee, Jung Kil; Kim, In Soo; Ha, Yoon; Im, Soo Bin; Kim, Sang Woo; Han, In Ho; Shin, Jun Jae; Rim, Byeong Cheol; Suk, Kyung Soo; Kim, Jin Hyok; Park, Ye Soo; Chang, Bong Soon; Jun, Deuk Soo; Kim, Young Hoon; Lee, Jung Hee; Min, Woo Kie; Lee, Jung Sub; Park, Si Young; Oh, In Soo; Hong, Jae-Young; Seo, Bo Jeong; Kim, Young Joo; Lee, Juneyoung.

In: Medicine, Vol. 97, No. 35, 01.08.2018, p. e11919.

Research output: Contribution to journalArticle

Hong, JT, Kim, JH, Kim, KS, Lee, CS, Shin, HC, Kim, WK, Kim, JH, Lee, JK, Kim, IS, Ha, Y, Im, SB, Kim, SW, Han, IH, Shin, JJ, Rim, BC, Suk, KS, Kim, JH, Park, YS, Chang, BS, Jun, DS, Kim, YH, Lee, JH, Min, WK, Lee, JS, Park, SY, Oh, IS, Hong, J-Y, Seo, BJ, Kim, YJ & Lee, J 2018, 'Pharmacological target therapy of neuropathic pain and patient-reported outcomes in patients with chronic low back pain in Korea: Results from the NLBP Outcomes Research', Medicine, vol. 97, no. 35, pp. e11919. https://doi.org/10.1097/MD.0000000000011919
Hong, Jae Taek ; Kim, Jin Hwan ; Kim, Keun Su ; Lee, Chong Suh ; Shin, Hyun Chul ; Kim, Woo Kyung ; Kim, Joo Han ; Lee, Jung Kil ; Kim, In Soo ; Ha, Yoon ; Im, Soo Bin ; Kim, Sang Woo ; Han, In Ho ; Shin, Jun Jae ; Rim, Byeong Cheol ; Suk, Kyung Soo ; Kim, Jin Hyok ; Park, Ye Soo ; Chang, Bong Soon ; Jun, Deuk Soo ; Kim, Young Hoon ; Lee, Jung Hee ; Min, Woo Kie ; Lee, Jung Sub ; Park, Si Young ; Oh, In Soo ; Hong, Jae-Young ; Seo, Bo Jeong ; Kim, Young Joo ; Lee, Juneyoung. / Pharmacological target therapy of neuropathic pain and patient-reported outcomes in patients with chronic low back pain in Korea : Results from the NLBP Outcomes Research. In: Medicine. 2018 ; Vol. 97, No. 35. pp. e11919.
@article{eee4c2e13d0d49548c02d8aa436825c1,
title = "Pharmacological target therapy of neuropathic pain and patient-reported outcomes in patients with chronic low back pain in Korea: Results from the NLBP Outcomes Research",
abstract = "A number of studies have demonstrated an association of neuropathic pain and chronic low back pain (CLBP), but the outcome difference in each medical management is poorly understood. This study is aimed to investigate treatment patterns of neuropathic pain in CLBP patients and to explore patient-reported outcomes (PROs) including quality of life (QoL) and functional disability by treatment patterns.Data were extracted from the neuropathic low back pain (NLBP) outcomes research. It was a multicenter and cross-sectional study in which 1200 patients were enrolled at 27 general hospitals, from 2014 to 2015. Of total, 478 patients classified as neuropathic pain were used for this subgroup analysis. The patients were divided into 2 groups according to treatment patterns (with vs. without the targeted therapy [TT] of neuropathic pain). Demographic and clinical features were collected by chart reviews and PROs were measured by patient's survey. QoL was assessed by EuroQoL 5-dimension (EQ-5D) questionnaire. Functional disability was measured by the Quebec Back Pain Disability Scale (QBPDS). Multiple linear regression analyses were conducted to compare the PROs between TT group and non-targeted therapy (nTT) group.Among the NLBP patients (mean age 63years, female 62{\%}), EQ-5D index, EuroQoL-Visual Analog Scale (EQ-VAS), and QBPDS Scores (mean ± standard deviation) were 0.40 ± 0.28, 54.98 ± 19.98, and 46.03 ± 21.24, respectively. Only 142 (29.7{\%}) patients had pharmacological TT of neuropathic pain. Univariate analyses revealed no significant mean differences between TT group and nTT group in the EQ-5D index (0.41 ± 0.27 and 0.39 ± 0.28), EQ-VAS (56.43 ± 18.17 and 54.37 ± 20.69), and QBPDS (45.31 ± 21.32 and 46.31 ± 21.24). After adjustment with covariates, TT group had higher scores of EQ-5D index (β = 0.07; P < 0.01) and EQ-VAS (β = 4.59; P < 0.05) than the nTT group. The TT group's QBPDS score was lower than the nTT group, although its statistical significance still has not been reached (β = -4.13; P = 0.07).We found that considerable proportion of the NLBP patients remains untreated or undertreated. Although TT group had significantly better QoL than nTT group, only 29.7{\%} of NLBP patients had pharmacological TT. Therefore, clinicians should consider using TT for better QoL of neuropathic pain patients.",
author = "Hong, {Jae Taek} and Kim, {Jin Hwan} and Kim, {Keun Su} and Lee, {Chong Suh} and Shin, {Hyun Chul} and Kim, {Woo Kyung} and Kim, {Joo Han} and Lee, {Jung Kil} and Kim, {In Soo} and Yoon Ha and Im, {Soo Bin} and Kim, {Sang Woo} and Han, {In Ho} and Shin, {Jun Jae} and Rim, {Byeong Cheol} and Suk, {Kyung Soo} and Kim, {Jin Hyok} and Park, {Ye Soo} and Chang, {Bong Soon} and Jun, {Deuk Soo} and Kim, {Young Hoon} and Lee, {Jung Hee} and Min, {Woo Kie} and Lee, {Jung Sub} and Park, {Si Young} and Oh, {In Soo} and Jae-Young Hong and Seo, {Bo Jeong} and Kim, {Young Joo} and Juneyoung Lee",
year = "2018",
month = "8",
day = "1",
doi = "10.1097/MD.0000000000011919",
language = "English",
volume = "97",
pages = "e11919",
journal = "Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries",
issn = "0025-7974",
publisher = "Lippincott Williams and Wilkins",
number = "35",

}

TY - JOUR

T1 - Pharmacological target therapy of neuropathic pain and patient-reported outcomes in patients with chronic low back pain in Korea

T2 - Results from the NLBP Outcomes Research

AU - Hong, Jae Taek

AU - Kim, Jin Hwan

AU - Kim, Keun Su

AU - Lee, Chong Suh

AU - Shin, Hyun Chul

AU - Kim, Woo Kyung

AU - Kim, Joo Han

AU - Lee, Jung Kil

AU - Kim, In Soo

AU - Ha, Yoon

AU - Im, Soo Bin

AU - Kim, Sang Woo

AU - Han, In Ho

AU - Shin, Jun Jae

AU - Rim, Byeong Cheol

AU - Suk, Kyung Soo

AU - Kim, Jin Hyok

AU - Park, Ye Soo

AU - Chang, Bong Soon

AU - Jun, Deuk Soo

AU - Kim, Young Hoon

AU - Lee, Jung Hee

AU - Min, Woo Kie

AU - Lee, Jung Sub

AU - Park, Si Young

AU - Oh, In Soo

AU - Hong, Jae-Young

AU - Seo, Bo Jeong

AU - Kim, Young Joo

AU - Lee, Juneyoung

PY - 2018/8/1

Y1 - 2018/8/1

N2 - A number of studies have demonstrated an association of neuropathic pain and chronic low back pain (CLBP), but the outcome difference in each medical management is poorly understood. This study is aimed to investigate treatment patterns of neuropathic pain in CLBP patients and to explore patient-reported outcomes (PROs) including quality of life (QoL) and functional disability by treatment patterns.Data were extracted from the neuropathic low back pain (NLBP) outcomes research. It was a multicenter and cross-sectional study in which 1200 patients were enrolled at 27 general hospitals, from 2014 to 2015. Of total, 478 patients classified as neuropathic pain were used for this subgroup analysis. The patients were divided into 2 groups according to treatment patterns (with vs. without the targeted therapy [TT] of neuropathic pain). Demographic and clinical features were collected by chart reviews and PROs were measured by patient's survey. QoL was assessed by EuroQoL 5-dimension (EQ-5D) questionnaire. Functional disability was measured by the Quebec Back Pain Disability Scale (QBPDS). Multiple linear regression analyses were conducted to compare the PROs between TT group and non-targeted therapy (nTT) group.Among the NLBP patients (mean age 63years, female 62%), EQ-5D index, EuroQoL-Visual Analog Scale (EQ-VAS), and QBPDS Scores (mean ± standard deviation) were 0.40 ± 0.28, 54.98 ± 19.98, and 46.03 ± 21.24, respectively. Only 142 (29.7%) patients had pharmacological TT of neuropathic pain. Univariate analyses revealed no significant mean differences between TT group and nTT group in the EQ-5D index (0.41 ± 0.27 and 0.39 ± 0.28), EQ-VAS (56.43 ± 18.17 and 54.37 ± 20.69), and QBPDS (45.31 ± 21.32 and 46.31 ± 21.24). After adjustment with covariates, TT group had higher scores of EQ-5D index (β = 0.07; P < 0.01) and EQ-VAS (β = 4.59; P < 0.05) than the nTT group. The TT group's QBPDS score was lower than the nTT group, although its statistical significance still has not been reached (β = -4.13; P = 0.07).We found that considerable proportion of the NLBP patients remains untreated or undertreated. Although TT group had significantly better QoL than nTT group, only 29.7% of NLBP patients had pharmacological TT. Therefore, clinicians should consider using TT for better QoL of neuropathic pain patients.

AB - A number of studies have demonstrated an association of neuropathic pain and chronic low back pain (CLBP), but the outcome difference in each medical management is poorly understood. This study is aimed to investigate treatment patterns of neuropathic pain in CLBP patients and to explore patient-reported outcomes (PROs) including quality of life (QoL) and functional disability by treatment patterns.Data were extracted from the neuropathic low back pain (NLBP) outcomes research. It was a multicenter and cross-sectional study in which 1200 patients were enrolled at 27 general hospitals, from 2014 to 2015. Of total, 478 patients classified as neuropathic pain were used for this subgroup analysis. The patients were divided into 2 groups according to treatment patterns (with vs. without the targeted therapy [TT] of neuropathic pain). Demographic and clinical features were collected by chart reviews and PROs were measured by patient's survey. QoL was assessed by EuroQoL 5-dimension (EQ-5D) questionnaire. Functional disability was measured by the Quebec Back Pain Disability Scale (QBPDS). Multiple linear regression analyses were conducted to compare the PROs between TT group and non-targeted therapy (nTT) group.Among the NLBP patients (mean age 63years, female 62%), EQ-5D index, EuroQoL-Visual Analog Scale (EQ-VAS), and QBPDS Scores (mean ± standard deviation) were 0.40 ± 0.28, 54.98 ± 19.98, and 46.03 ± 21.24, respectively. Only 142 (29.7%) patients had pharmacological TT of neuropathic pain. Univariate analyses revealed no significant mean differences between TT group and nTT group in the EQ-5D index (0.41 ± 0.27 and 0.39 ± 0.28), EQ-VAS (56.43 ± 18.17 and 54.37 ± 20.69), and QBPDS (45.31 ± 21.32 and 46.31 ± 21.24). After adjustment with covariates, TT group had higher scores of EQ-5D index (β = 0.07; P < 0.01) and EQ-VAS (β = 4.59; P < 0.05) than the nTT group. The TT group's QBPDS score was lower than the nTT group, although its statistical significance still has not been reached (β = -4.13; P = 0.07).We found that considerable proportion of the NLBP patients remains untreated or undertreated. Although TT group had significantly better QoL than nTT group, only 29.7% of NLBP patients had pharmacological TT. Therefore, clinicians should consider using TT for better QoL of neuropathic pain patients.

UR - http://www.scopus.com/inward/record.url?scp=85052829005&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052829005&partnerID=8YFLogxK

U2 - 10.1097/MD.0000000000011919

DO - 10.1097/MD.0000000000011919

M3 - Article

VL - 97

SP - e11919

JO - Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries

JF - Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries

SN - 0025-7974

IS - 35

ER -